Organogenesis Holdings (ORGO) Change in Receivables (2016 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Change in Receivables of -$104.5 million for Q1 2026, down 1743.72% year-over-year from $6.4 million in Q1 2025, and down 303.0% quarter-over-quarter from $51.5 million in Q4 2025.
Organogenesis Holdings (ORGO) Change in Receivables (2016 - 2026) Analysis & Trends
Organogenesis Holdings' Change in Receivables history runs 11 years deep, the most recent figure standing at -$104.5 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 1743.72% year-over-year to -$104.5 million; the TTM figure through Mar 2026 stood at $17.0 million (up 54.05% YoY), while the FY2025 annual figure was $115.8 million, up 264.16% from the prior year.
- Change in Receivables for Q1 2026 stood at -$104.5 million, down from $51.5 million in the prior quarter.
- The five-year high for Change in Receivables was $51.5 million in Q4 2025, with the low at -$104.5 million in Q1 2026.
- The 5-year median for Change in Receivables is $3.4 million (2023), against an average of $2.7 million.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables surged 1799.8% in 2025, then slumped 1743.72% in 2026.
- Organogenesis Holdings' Change in Receivables stood at -$2.7 million in 2022, then slumped by 166.42% to -$7.3 million in 2023, then jumped by 220.6% to $8.8 million in 2024, then jumped by 484.71% to $51.5 million in 2025, then sank by 303.0% to -$104.5 million in 2026.
- Business Quant data shows ORGO's Change in Receivables at -$104.5 million in Q1 2026, $51.5 million in Q4 2025, and $50.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Organogenesis Holdings | 241.91 Mn | 195.06 Mn | 20.08 Mn | -14.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.99 Mn |
| Jun 30, 2026 | -14.99 Mn |
| Mar 31, 2026 | -104.50 Mn |
| Mar 31, 2026 | -104.50 Mn |
| Dec 31, 2025 | 51.48 Mn |
| Dec 31, 2025 | 51.48 Mn |
| Sep 30, 2025 | 50.69 Mn |
| Sep 30, 2025 | 50.69 Mn |
| Jun 30, 2025 | 19.31 Mn |
| Jun 30, 2025 | 19.31 Mn |
| Mar 31, 2025 | -5.67 Mn |
| Mar 31, 2025 | -5.67 Mn |
| Dec 31, 2024 | 8.80 Mn |
| Dec 31, 2024 | 8.80 Mn |
| Sep 30, 2024 | -2.98 Mn |
| Sep 30, 2024 | -2.98 Mn |
| Jun 30, 2024 | 10.86 Mn |
| Jun 30, 2024 | 10.86 Mn |
| Mar 31, 2024 | 15.12 Mn |
| Mar 31, 2024 | 15.12 Mn |